Lynch Regenerative Medicine Introduces Syringe2Syringe Ariessence Pure PDGF+ Kit 

Lynch Regenerative Medicine soft-launched its new Syringe2Syringe Ariessence pure PDGF+ kit at the 2026 Music City SCALE Symposium in Nashville, TN. 

Ariessence pure PDGF+ comprises a proprietary, pure, recombinant, and sterile platelet-derived growth factor (PDGF) and a proprietary blend of sterile hyaluronic acid (HA) to enhance post-procedural wound healing. 

The new kit eliminates the need to manually draw up hyaluronic acid. Each sterile pack is designed for single-patient use, allowing PDGF+ and hyaluronic acid to be mixed seamlessly in 20 seconds. 

Speaking at a media event in New York City, Lynch Regenerative Medicine Founder and CEO Samuel Lynch, DMSc, DMD, previewed what to expect from the company in the coming years. “We hope to start a US Food and Drug Administration (FDA)-approved clinical trial of injectable PDGF+ for the under-eye area and make Ariessence pure PDGF+ the standard of post-procedural care, especially after CO2 laser skin resurfacing and more aggressive procedures.”

The company already has four products containing PDGF that are FDA approved, including Augment Bone Graft, Augment Injectable, GEM 21S, and Regranex (becaplermin) gel.